Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

Hao Wang, Gurbakhash Kaur, Alexander I. Sankin, Fuxiang Chen, Fangxia Guan, Xingxing Zang

Research output: Contribution to journalReview articlepeer-review

94 Scopus citations


Harnessing the power of the immune system to recognize and eliminate cancer cells is a longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and chimeric antigen receptor T (CAR-T) cell therapy have proven to be safe and effective in hematologic malignancies. Despite the unprecedented success of ICB and CAR-T therapy, only a subset of patients can benefit partially due to immune dysfunction and lack of appropriate targets. Here, we review the preclinical and clinical advances of CTLA-4 and PD-L1/PD-1-based ICB and CD19-specific CAR-T cell therapy in hematologic malignancies. We also discuss the basic research and ongoing clinical trials on emerging immune checkpoints (Galectin-9/Tim-3, CD70/CD27, LAG-3, and LILRBs) and on new targets for CAR-T cell therapy (CD22, CD33, CD123, BCMA, CD38, and CD138) for the treatment of hematologic malignancies.

Original languageEnglish (US)
Article number59
JournalJournal of Hematology and Oncology
Issue number1
StatePublished - Jun 11 2019


  • CAR-T
  • CTLA-4
  • Hematologic malignancies
  • Immune checkpoints
  • Immunotherapy
  • New targets
  • PD-1

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies'. Together they form a unique fingerprint.

Cite this